Literature DB >> 29025017

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

James R Cerhan1, Brian K Link2, Thomas M Habermann3, Matthew J Maurer1, Andrew L Feldman4, Sergei I Syrbu5, Carrie A Thompson3, Umar Farooq2, Anne J Novak3, Susan L Slager1, Cristine Allmer1, Julianne J Lunde1, William R Macon4, David J Inwards3, Patrick B Johnston3, Ivana N M Micallef3, Grzegorz S Nowakowski3, Stephen M Ansell3, Neil E Kay3, George J Weiner2, Thomas E Witzig3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29025017      PMCID： PMC5837578          DOI： 10.1093/ije/dyx119

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN： 0300-5771            Impact factor:   7.196


× No keyword cloud information.
  54 in total

1.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  H Tilly; M Gomes da Silva; U Vitolo; A Jack; M Meignan; A Lopez-Guillermo; J Walewski; M André; P W Johnson; M Pfreundschuh; M Ladetto
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

2.  Diffuse Large B-Cell Lymphoma Version 1.2016.

Authors:  Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Luis E Fayad; Richard I Fisher; Martha J Glenn; Thomas M Habermann; Nancy Lee Harris; Francisco Hernandez-Ilizaliturri; Richard T Hoppe; Steven M Horwitz; Mark S Kaminski; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Matthew Lunning; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Kenneth Roberts; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Julie M Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-02       Impact factor: 11.908

3.  BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Authors:  Cristina Correia; Paula A Schneider; Haiming Dai; Ahmet Dogan; Matthew J Maurer; Amy K Church; Anne J Novak; Andrew L Feldman; Xiaosheng Wu; Husheng Ding; X Wei Meng; James R Cerhan; Susan L Slager; William R Macon; Thomas M Habermann; Judith E Karp; Steven D Gore; Neil E Kay; Diane F Jelinek; Thomas E Witzig; Grzegorz S Nowakowski; Scott H Kaufmann
Journal:  Blood       Date:  2014-12-01       Impact factor: 22.113

4.  Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP.

Authors:  Panagiotis Samaras; Helen Heider; Sarah R Haile; Ulf Petrausch; Niklaus G Schaefer; Raffaele Daniele Siciliano; Alexander Meisel; Axel Mischo; Martin Zweifel; Alexander Knuth; Frank Stenner-Liewen; Christoph Renner
Journal:  Ann Hematol       Date:  2010-03-05       Impact factor: 3.673

5.  Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Matthew J Maurer; Hervé Ghesquières; Jean-Philippe Jais; Thomas E Witzig; Corinne Haioun; Carrie A Thompson; Richard Delarue; Ivana N Micallef; Frédéric Peyrade; William R Macon; Thierry Jo Molina; Nicolas Ketterer; Sergei I Syrbu; Olivier Fitoussi; Paul J Kurtin; Cristine Allmer; Emmanuelle Nicolas-Virelizier; Susan L Slager; Thomas M Habermann; Brian K Link; Gilles Salles; Hervé Tilly; James R Cerhan
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

6.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Authors:  Matthew J Maurer; Emmanuel Bachy; Hervé Ghesquières; Stephen M Ansell; Grzegorz S Nowakowski; Carrie A Thompson; David J Inwards; Cristine Allmer; Catherine Chassagne-Clément; Emmanuelle Nicolas-Virelizier; Catherine Sebban; Laure Lebras; Clementine Sarkozy; William R Macon; Andrew L Feldman; Sergei I Syrbu; Alexandra Traverse-Glehan; Bertrand Coiffier; Susan L Slager; George J Weiner; Thomas E Witzig; Thomas M Habermann; Gilles Salles; James R Cerhan; Brian K Link
Journal:  Am J Hematol       Date:  2016-09-03       Impact factor: 10.047

7.  Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study.

Authors:  Jonathan W Friedberg; Michelle Byrtek; Brian K Link; Christopher Flowers; Michael Taylor; John Hainsworth; James R Cerhan; Andrew D Zelenetz; Jamie Hirata; Thomas P Miller
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

Review 8.  Non-Hodgkin lymphoma.

Authors:  Kate R Shankland; James O Armitage; Barry W Hancock
Journal:  Lancet       Date:  2012-07-25       Impact factor: 79.321

9.  Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma.

Authors:  Thomas E Witzig; Matthew J Maurer; Thomas M Habermann; Brian K Link; Ivana N M Micallef; Grzegorz S Nowakowski; Stephen M Ansell; Joseph P Colgan; David J Inwards; Luis F Porrata; Svetomir N Markovic; Patrick B Johnston; Yi Lin; Carrie Thompson; Mamta Gupta; Jerry A Katzmann; James R Cerhan
Journal:  Am J Hematol       Date:  2014-09-26       Impact factor: 10.047

10.  RVboost: RNA-seq variants prioritization using a boosting method.

Authors:  Chen Wang; Jaime I Davila; Saurabh Baheti; Aditya V Bhagwate; Xue Wang; Jean-Pierre A Kocher; Susan L Slager; Andrew L Feldman; Anne J Novak; James R Cerhan; E Aubrey Thompson; Yan W Asmann
Journal:  Bioinformatics       Date:  2014-08-27       Impact factor: 6.937
View more
  36 in total

1.  Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.

Authors:  Yucai Wang; Matthew J Maurer; Melissa C Larson; Cristine Allmer; Andrew L Feldman; N Nora Bennani; Carrie A Thompson; Luis F Porrata; Thomas M Habermann; Thomas E Witzig; Stephen M Ansell; Susan L Slager; Grzegorz S Nowakowski; James R Cerhan
Journal:  Br J Haematol       Date:  2019-05-28       Impact factor: 6.998

2.  Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Authors:  Nancy L Bartlett; Wyndham H Wilson; Sin-Ho Jung; Eric D Hsi; Matthew J Maurer; Levi D Pederson; Mei-Yin C Polley; Brandelyn N Pitcher; Bruce D Cheson; Brad S Kahl; Jonathan W Friedberg; Louis M Staudt; Nina D Wagner-Johnston; Kristie A Blum; Jeremy S Abramson; Nishitha M Reddy; Jane N Winter; Julie E Chang; Ajay K Gopal; Amy Chadburn; Susan Mathew; Richard I Fisher; Kristy L Richards; Heiko Schöder; Andrew D Zelenetz; John P Leonard
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

3.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

4.  The association of physical activity before and after lymphoma diagnosis with survival outcomes.

Authors:  Priyanka A Pophali; Andrew Ip; Melissa C Larson; Allison C Rosenthal; Matthew J Maurer; Christopher R Flowers; Brian K Link; Umar Farooq; Andrew L Feldman; Cristine Allmer; Susan L Slager; Thomas E Witzig; Thomas M Habermann; Jonathon B Cohen; James R Cerhan; Carrie A Thompson
Journal:  Am J Hematol       Date:  2018-10-17       Impact factor: 10.047

5.  Novel Insights Into the Long-Term Immune Health of Diffuse Large B-Cell Lymphoma Survivors.

Authors:  Lindsay M Morton
Journal:  J Clin Oncol       Date:  2020-03-31       Impact factor: 44.544

6.  Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma.

Authors:  Yucai Wang; Brian K Link; Thomas E Witzig; Matthew J Maurer; Cristine Allmer; Rebecca L King; Andrew L Feldman; Thomas M Habermann; Stephen M Ansell; Susan L Slager; James R Cerhan; Grzegorz S Nowakowski
Journal:  Blood       Date:  2019-10-17       Impact factor: 22.113

7.  Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Authors:  Matthew J Maurer; Hervé Ghesquières; Brian K Link; Jean-Philippe Jais; Thomas M Habermann; Carrie A Thompson; Corinne Haioun; Cristine Allmer; Patrick B Johnston; Richard Delarue; Ivana N Micallef; Frederic Peyrade; David J Inwards; Nicolas Ketterer; Umar Farooq; Olivier Fitoussi; William R Macon; Thierry J Molina; Sergei Syrbu; Andrew L Feldman; Susan L Slager; George J Weiner; Stephen M Ansell; James R Cerhan; Gilles A Salles; Thomas E Witzig; Hervé Tilly; Grzegorz S Nowakowski
Journal:  J Clin Oncol       Date:  2018-04-19       Impact factor: 44.544

8.  A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.

Authors:  Emmanuel Bachy; Matthew J Maurer; Thomas M Habermann; Bénédicte Gelas-Dore; Delphine Maucort-Boulch; Jane A Estell; Eric Van den Neste; Réda Bouabdallah; Emmanuel Gyan; Andrew L Feldman; Joan Bargay; Alain Delmer; Susan L Slager; Maria Gomes da Silva; Olivier Fitoussi; David Belada; Hervé Maisonneuve; Tanin Intragumtornchai; Stephen M Ansell; Thierry Lamy; Peggy Dartigues; Brian K Link; John F Seymour; James R Cerhan; Gilles Salles
Journal:  Blood       Date:  2018-04-17       Impact factor: 22.113

9.  Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.

Authors:  Clémentine Sarkozy; Matthew J Maurer; Brian K Link; Hervé Ghesquieres; Emmanuelle Nicolas; Carrie A Thompson; Alexandra Traverse-Glehen; Andrew L Feldman; Cristine Allmer; Susan L Slager; Stephen M Ansell; Thomas M Habermann; Emmanuel Bachy; James R Cerhan; Gilles Salles
Journal:  J Clin Oncol       Date:  2018-11-27       Impact factor: 44.544

10.  Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.

Authors:  Alberto Risueño; Patrick R Hagner; Fadi Towfic; Celia Fontanillo; Amira Djebbari; Joel S Parker; Clifton P Drew; Grzegorz S Nowakowski; Matthew J Maurer; James R Cerhan; Xin Wei; Yan Ren; Chung-Wein Lee; Suzana Couto; Maria Wang; Michael Pourdehnad; Anita K Gandhi; Matthew W B Trotter
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.